COMMUNIQUÉS West-GlobeNewswire

Les résultats semestriels confirment la pertinence de la stratégie de Roquette
25/09/2025
Les résultats semestriels confirment la pertinence de la stratégie de Roquette Roquette surperforme ses principaux marchés et enregistre des résultats solides au premier semestre dans des conditions de marché complexes [...]
Fagron announces the acquisition of UCP in North America and FDA inspection update
25/09/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 25 September 2025 – 7:00 AM CET Fagron announces the acquisition of UCP in North America and FDA inspection update Fagron, the [...]
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
25/09/2025
- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, [...]
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001
25/09/2025
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling it to go [...]
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
25/09/2025
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc (“Arecor” or the “Company”) Co-development [...]
GUERBET : Mise à disposition du rapport financier semestriel 2025
25/09/2025
Mise à disposition du rapport financier semestriel 2025 Villepinte, le 25 septembre 2025 – Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, annonce ce jour [...]
Summary Notice of Proposed Settlement of Derivative Actions
25/09/2025
LEHI, Utah, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Owlet, Inc. (NYSE:OWLT) has released the following notice: IN THE UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA IN RE OWLET, INC. SHAREHOLDER [...]
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
25/09/2025
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public [...]
H1 25 Results Confirm the Relevance of Roquette’s Strategy
25/09/2025
H1 25 Results Confirm the Relevance of Roquette’s Strategy Roquette outperforms its key markets, delivering solid H1 results in current complex market conditions. Successful completion of the acquisition of IFF Pharma [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
25/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor ® , FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
25/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor ® , FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, [...]
MBX Biosciences Announces Pricing of Upsized Public Offering
25/09/2025
CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Inventiva organise un événement analystes et investisseurs le 8 octobre 2025
24/09/2025
Le programme inclura une mise à jour sur son médicament candidat, lanifibranor, en amont des résultats principaux de l’étude de Phase 3 NATiV3 attendus au second semestre 2026 Trois experts internationaux de renom et un [...]
Inventiva to Host Analyst and Investor Event on October 8, 2025
24/09/2025
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026 Three renowned international experts and a patient representative [...]
CROSSJECT presents its financial results and key highlights for the first half of 2025
24/09/2025
Press release CROSSJECT presents its financial results and key highlights for the first half of 2025 Cash position: €6.3 million, compared to €7.0 million as of December 31 2024, demonstrating the Company's excellent [...]
CROSSJECT présente ses résultats financiers et les principaux faits marquants pour le premier semestre 2025
24/09/2025
Communiqué de presse CROSSJECT présente ses résultats financiers et les principaux faits marquants pour le premier semestre 2025 Position de trésorerie : 6.3 millions d'euros, contre 7,0 millions d’euros au 31 décembre [...]
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
24/09/2025
- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory [...]
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
24/09/2025
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. [...]
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
24/09/2025
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of [...]

Pages